Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies

Tao Shi; Hanbing Wang; Jia Wei; Jinyan Wang; Yibo Fan; Chunlei Zheng; Xiaofang Che

doi:10.3389/fimmu.2023.1230591

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies

Front Immunol. 2023 Jun 7:14:1230591. doi: 10.3389/fimmu.2023.1230591. eCollection 2023.

Authors

Tao Shi¹, Hanbing Wang¹, Jia Wei¹, Jinyan Wang², Yibo Fan³, Chunlei Zheng⁴, Xiaofang Che^{5

6

7}

Affiliations

¹ Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
² Department of Immunology, Basic School of Medicine, China Medical University, Shenyang, China.
³ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁴ Department of Oncology, Shanghai Electric Power Hospital, Shanghai, China.
⁵ Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
⁶ Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
⁷ Clinical Cancer Research Center of Shenyang, the First Hospital of China Medical University, Shenyang, China.

No abstract available

Keywords: gastrointestinal cancer; immune checkpoint blockade; resistance; tumor immunotherapy; tumor microenvironment.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Drug Resistance
Gastrointestinal Neoplasms* / therapy
Humans
Immunotherapy

Grants and funding

This work is supported by the National Natural Science Foundation of China (No. 32170791) and the Research Project of Education Department of Liaoning Province (No.ZD2020001).